Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654081 | 0.83 | ALDH1A1 (0.66) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL1605140 | 0.83 | ALDH1A1 (0.66) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL11081105 | 0.83 | MEN1 (0.58) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL27500298 | 0.82 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL11376816 | 0.82 | L3MBTL1 (0.42) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL6835352 | 0.81 | LMNA (0.70) | ALDH1A1LMNAKDM4EMAPTHPGD | |
| SCHEMBL6833525 | 0.81 | L3MBTL1 (0.47) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL4974735 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL790145 | 0.81 | L3MBTL1 (0.47) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL6969191 | 0.80 | MEN1 (0.61) | MEN1KMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113646049-B | Pyrimidinone derivatives as SHP2 antagonists | 默克专利有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240140931-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4288436-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116940573-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| CN-114432901-A | Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3952998-A1 | PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS | Merck Patent GmbH (DE) | 2022-02-16 | — | — | EP | disclosed |
| CN-113646049-A | Pyrimidone derivatives as SHP2 antagonists | 默克专利有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | MEN1 91/4885KMT2A 4700/4885ALDH1A1 3467/4885 |
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | PTPN5, PTPN1, PTPN2 | MEN1 2140/4885KMT2A 926/4885ALDH1A1 2296/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | MEN1 2168/4885KMT2A 2992/4885ALDH1A1 3209/4885 |
| US-20240140931-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | CYP2C19, CYP3A7, CYP11B2 | MEN1 942/4885KMT2A 3525/4885ALDH1A1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.